Khaliq et al. defend that epigenetic mechanisms could influence the progression of BRAF mutated cancers and MAPK inhibitor resistance, so knowledge of the epigenetic changes might enable us to know the dependence on BRAF status and find new effective therapies [29]. The gene discussed is BRAF; the disease is cancer.